This study will continue to treat and collect safety and efficacy data on patients who
participated in Glaxo-Wellcome's multi-center study on combination therapy with abacavir,
amprenavir and efavirenz (A Phase II Study Evaluating the Safety and Antiviral Activity of
Combination Therapy with 1592U89, 141W94 and DMP 266 (Sustiva) in HIV-1 Infected Subjects
with Detectable [greater than 400 Copies/mL] HIV-1 Plasma RNA Despite Treatment with a
Protease Inhibitor-Containing Regimen).
HIV-infected patients 18 years of age and older who participated in the above study at the
NIH site may be eligible for the current study. Participants will be followed every 3 months
with a general health evaluation and laboratory tests. This is a NIH study, and information
will not be provided to Glaxo Wellcome
In this open-label, single-arm study, HIV-1 infected patients who had, at study entry, a
viral burden of at least 500 copies/mL despite 20 weeks of treatment with a protease
inhibitor receive combination therapy with three antiretroviral agents that were
investigational at the start of study but have since been approved: abacavir, amprenavir,
and efavirenz. At the end of 16 weeks, the addition of other antiretroviral agents to the
study regimen was permitted. This was originally a multi-center study, but it has been
closed at all other sites. It remains open at the NIH to continue to provide therapy to
subjects who have received benefit as determined by a decline in viral load from baseline.
Safety and viral load data continue to be collected.
Subjects who were previously enrolled in this protocol when it was a multi-center study
and who signed the new informed consent were enrolled. There has been and will be no
other new enrollment. Thus, subjects who were not previously enrolled are excluded.
Subjects are adults infected with HIV-1 who had, prior to study enrollment, a plasma viral
load of at least 500 copies/mL despite at least 20 weeks of treatment with a protease
inhibitor and without change in protease inhibitor therapy in the 12 weeks prior to